HeartBeam to Discuss Q3 2025 Results and Cardiac Technology Milestones in November Conference Call

HeartBeam, a medical technology company trading on NASDAQ under the symbol BEAT, has scheduled a conference call for November 13, 2025, at 4:30 p.m. ET to discuss its third quarter financial results for the period ended September 30, 2025. The company will also provide updates on regulatory progress, commercial-readiness activities, and upcoming milestones during the call. A detailed press release containing the quarterly results will be issued prior to the conference call, which investors and stakeholders can access through the company's newsroom at https://ibn.fm/BEAT.

The significance of this announcement extends beyond routine quarterly earnings discussions, as HeartBeam represents a transformative force in cardiac care technology. The company is developing the first-ever cable-free device capable of collecting electrocardiogram signals in three dimensions from three non-coplanar directions and synthesizing these signals into a comprehensive 12-lead ECG. This technological advancement marks a substantial shift in how cardiac conditions can be detected and monitored, moving cardiac care from traditional medical facilities to portable devices that can be used wherever patients are located.

HeartBeam's platform technology has already achieved important regulatory milestones, with the 3D ECG technology receiving FDA clearance for arrhythmia assessment in December 2024. The company's 12-Lead ECG synthesis software remains under FDA review, representing a critical next step in bringing this innovative technology to market. The regulatory progress updates expected during the November conference call will provide important insights into the company's path toward commercialization and broader market adoption.

The potential impact of HeartBeam's technology on cardiac healthcare is substantial. Physicians utilizing this technology will be able to identify cardiac health trends and acute conditions while directing patients to appropriate care entirely outside traditional medical facilities. This capability could revolutionize cardiac health management by enabling earlier detection of problems, continuous monitoring of at-risk patients, and reducing the burden on healthcare facilities. The technology's portability means that cardiac monitoring can occur in homes, workplaces, or any location where patients spend time, potentially catching cardiac events that might otherwise go undetected until reaching emergency situations.

HeartBeam's intellectual property portfolio includes over 20 issued patents related to technology enablement, providing the company with significant protection for its innovations. This robust patent position strengthens the company's competitive advantage in the growing digital health and remote patient monitoring markets. The commercial-readiness activities to be discussed in the upcoming call will shed light on how the company plans to leverage this technology platform and intellectual property to capture market share in the evolving cardiac care landscape.

Investors and industry observers should note that the company's forward-looking statements involve risks and uncertainties, as detailed in the company's SEC filings available through https://ibn.fm/Disclaimer. These factors may cause actual results to differ from current expectations and projections. The upcoming conference call will provide the investment community with crucial information about HeartBeam's financial performance, regulatory timeline, and strategic direction as the company works to transform cardiac care through personalized insights and portable monitoring technology.